BLMH/Bleomycin Hydrolase Antibody (760239) [Unconjugated]

Western blot shows lysates of MOLT-4 human acute lymphoblastic leukemia cell line, mouse pancreas tissue, and rat pancreas tissue. PVDF membrane was probed with 0.2 µg/mL of Mouse Anti-Human BLMH/Bleomycin Hydrolase Monoclonal Antibody (Catalog # MAB6200) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for BLMH/Bleomycin Hydrolase at approximately 52 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

BLMH/Bleomycin Hydrolase was detected in immersion fixed paraffin-embedded sections of human testis using Mouse Anti-Human BLMH/Bleomycin Hydrolase Monoclonal Antibody (Catalog # MAB6200) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to spermatocytes. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and BLMH/Bleomycin Hydrolase knockout HeLa cell line (KO). PVDF membrane was probed with 0.2 µg/mL of Mouse Anti-Human BLMH/Bleomycin Hydrolase Monoclonal Antibody (Catalog # MAB6200) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for BLMH/Bleomycin Hydrolase at approximately 51 kDa (as indicated) in the parental HeLa cell line, but is not detectable in knockout HeLa cell line. GAPDH (Catalog # MAB5718) is shown as a loading control. This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

• Reactivity: Hu
• Applications: WB, IHC, KO
• Clone: 760239
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

BLMH/Bleomycin Hydrolase Antibody (760239) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human BLMH/Bleomycin Hydrolase
  Ser2-Glu455
  Accession # Q13867
• Specificity: Detects human BLMH/Bleomycin Hydrolase in direct ELISAs. It detects human, mouse and rat BLMH/Bleomycin Hydrolase in Western Blots.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: BLMH
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 8-25 ug/mL
  • Knockout Validated
  • Western Blot 0.2 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Sterile PBS to a final concentration of 0.5 mg/mL.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for BLMH/Bleomycin Hydrolase Antibody (760239) [Unconjugated]

• BHBMHBLM hydrolase
• bleomycin hydrolase
• BLMH
• BMH
• EC 3.4.22.40

Background

Bleomycin Hydrolase (BLMH) is a cysteine peptidase of the papain superfamily. It is named for its ability to hydrolyze the antitumor agent bleomycin and inactivate it (1). It has a papain-like catalytic triad (Cys-His-Asp) with optimum activity at neutral pH. In mammals it is expressed ubiquitously in all types of tissues and its expression is up‑regulated in many tumors. It is present in the cytoplasm as homohexameric protein of approximately 300 kDa. In addition to its aminopeptidase activity, it has homocysteine-thiolactonase activity. BLMH inactivates bleomycin, a glycopeptide anticancer agent, by deaminating it (2). BLMH has been suggested to play a role in the generation of MHC class I-presented peptides (3, 4). Diminished BLMH activity may contribute to the pathology of Alzheimer’s disease (AD) (5, 6). It is inhibited by cysteine protease inhibitors such as N-ethylmaleimide, iodoacetamide, para-hydroxymercuribenzoate, and E‑64.

1. Joshua-Tor, L. and S. A. Johnson (2004) in Handbook of Proteolytic Enzymes, Barrett, A. J. et al. eds. pp. 1197.
2. Schwartz, D. R. et al. (1999) Proc. Natl. Acad. Sci. USA, 96:4680.
3. Kim, E. et al. (2009) J. Immunol. 183:7379.
4. Towne, C. F. et al. (2007) J. Immunol. 178:6923.
5. Suszynska, J. et al. (2010) J. Alzheimers Dis. 19:1177.
6. Lefterov, I. M. et al. (2000) FASEB J. 14:1837.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for BLMH/Bleomycin Hydrolase Antibody (MAB6200)(1)

Publication using MAB6200

• HX Zhang, Y Chen, R Xu, QY He Nrf2 mediates the resistance of human A549 and HepG2 cancer cells to boningmycin, a new antitumor antibiotic, in vitro through regulation of glutathione levels Acta Pharmacol. Sin., 2018-05-10;39(10):1661-1669. 2018-05-10 [PMID: 30287928] (Western Blot, Human)

Bioinformatics

• Gene Symbol: BLMH
• Uniprot:
  • Q13867()